Increasing incidence of early-onset type 2 diabetes in Sweden 2006–2021
Open Access
- 9 July 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 35 (6) , 1258-1263
Abstract
Our aim was to provide new data on the incidence, prevalence, and secular trend of type 2 diabetes (T2D) in Sweden, specifically early-onset T2D. We followed the Swedish population 2006 to 2021 and calculated age-standardized incidence (per 100 000) and prevalence (%) of T2D (overall) and early-onset T2D (age 23–39 years) stratified by sex, region of birth, and educational level. We projected the future prevalence of early-onset T2D by combining observed trends with population projections. From 2006 to 2021, the prevalence of T2D rose from 4.87% to 7.50%, and incidence from 477 [95% confidence interval (CI) 471–482] to 574 (CI 568–579). Early-onset T2D incidence increased from 54 to 107 (4.7% annual rise; CI 3.7%–5.7%) during this period. Incidence of early-onset T2D was higher in individuals born outside Europe (211, CI 195–226 vs 89, CI 84–93 in 2021) or low education (204, CI 185–223 vs 71, CI 65–77 in 2021), but a rise in incidence was seen irrespective of educational level, region of origin, and sex. If the incidence of early-onset T2D continues to increase at the same pace, its prevalence is projected to increase from 0.64% in 2021 to 3.2% in 2050. While T2D incidence rose marginally in Sweden 2006 to 2021, there was a significant rise in early-onset T2D, seen across different socioeconomic characteristics, with prevalence more than doubling and incidence nearly doubling. This development calls for targeted preventive efforts.Keywords
Funding Information
- Swedish Research Council (2022-00811)
- Swedish Diabetes Foundation (DIA2024-908)
- Strategic Research Area for Diabetes at Karolinska Institutet
This publication has 24 references indexed in Scilit:
- Eleven-year trends in socioeconomic inequalities in the prevalence and incidence of pharmacologically treated type 2 diabetes in France, 2010–2020Diabetes & Metabolism, 2024
- Incidence of type 2 diabetes before and during the COVID-19 pandemic in Naples, Italy: a longitudinal cohort studyeClinicalMedicine, 2023
- Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observationThe Lancet Diabetes & Endocrinology, 2023
- Current insights and emerging trends in early-onset type 2 diabetesThe Lancet Diabetes & Endocrinology, 2023
- Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2023
- Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: results from the population-based SEARCH for Diabetes in Youth studyThe Lancet Diabetes & Endocrinology, 2023
- Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort studyThe Lancet Diabetes & Endocrinology, 2021
- The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical researchEuropean Journal of Epidemiology, 2019
- Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohortThe Lancet Diabetes & Endocrinology, 2014
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006